AKT1 and lung adenocarcinoma: To identify genetic vulnerability of the mTORC2 pathway in LUSC, we first assessed the frequency of molecular alterations in PI3K and AKT signaling in the two predominant non-small cell lung cancer (NSCLC) subtypes, lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD).